Effects of fluvoxamine on nerve growth factor-induced neurite outgrowth inhibition by dexamethasone in PC12 cells

References

• Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry. 1994;164:365–371.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism. 2005;54:20–23.
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925–935.
   PubMed Web of Science ®Google Scholar
• Holsboer F, Lauer CJ, Schreiber W, et al. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology. 1995;62:340–347.
   PubMed Web of Science ®Google Scholar
• Liu HH, Payne HR, Wang B, et al. Gender differences in response of hippocampus to chronic glucocorticoid stress: role of glutamate receptors. J Neurosci Res. 2006;83:775–786.
   PubMed Web of Science ®Google Scholar
• Sousa N, Lukoyanov NV, Madeira MD, et al. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience. 2000;97:253–266.
   PubMed Web of Science ®Google Scholar
• Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates: from receptors to therapeutics. Immunology. 2009;1179:1–18.
   Google Scholar
• Kunugi H, Ida I, Owashi T, et al. Assessment of the dexamethasone/CRH test as a state-ependent Mamrker for hypothalamic-pituitary-adrenal (HPA) xis Abanormalities in major depressive episode: A multicenter study. Neuropsychopharmacology. 2005;31:212–220.
   Web of Science ®Google Scholar
• Wróbel A, Serefko A, Wlaź P, et al. The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:243–248.
   PubMed Web of Science ®Google Scholar
• Terada K, Kojima Y, Watanabe T, et al. Inhibition of nerve growth factor-induced neurite outgrowth from PC12 cells by dexamethasone: signaling pathways through the glucocorticoid receptor and phosphorylated Akt and ERK1/2. PLoS One. 2014;9:e93223.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Ishima T, Iyo M, et al. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008;3:e2558.
   PubMed Web of Science ®Google Scholar
• Bouquet C, Nothias F. Molecular mechanisms of axonal growth. Adv Exp Med Biol. 2007;621:1–16.
   PubMed Web of Science ®Google Scholar
• Hafner A, Obermajer N, Kos J. γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. Biochem J. 2012;443:439–450.
   PubMed Web of Science ®Google Scholar
• Read DE, Gorman AM. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci. 2009;66:2975–2984.
   PubMed Web of Science ®Google Scholar
• Zhao J, Cheng YY, Fan W, et al. Botanical drug puerarin coordinates with nerve growth factor in the regulation of neuronal survival and neuritogenesis via activating ERK1/2 and PI3K/Akt ignaling athways in the neurite extension process. CNS Neurosci Ther. 2015;21:61–70.
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Sakagami H, Yabuki Y, et al. Stimulation of sigma-1 receptor ameliorates depressive-like behaviors in CaMKIV null mice. Mol Neurobiol. 2015;52:1210–1222.
   PubMed Web of Science ®Google Scholar
• Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–173.
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307:117–119.
   PubMed Web of Science ®Google Scholar
• Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry. 2009;8:6–8.
   PubMedGoogle Scholar
• Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25:193–200.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res. 2010;3:25–36.
   Google Scholar
• Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharmacol Ther. 2009;124:195–206.
   PubMed Web of Science ®Google Scholar
• Budziszewska B, Jaworska-Feil L, Kajta M, et al. Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol. 2000;130:1385–1393.
   PubMed Web of Science ®Google Scholar
• Murphy BEP. Antiglucocorticoid therapies in major depression: A review. Psychoneuroendocrinology. 1997;22:125–132.
   Web of Science ®Google Scholar
• Okuyama S, Nakazato A. NE-100: A novel sigma receptor antagonist. CNS Drug Rev. 1996;2:226–237.
   Google Scholar